The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | Ibrutinib monotherapy in WM: long-term follow-up data
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the long-term follow-up data of ibrutinib monotherapy in patients with Waldenström’s macroglobulinemia (WM), commenting on the overall response rate (ORR) and very good partial response (VGPR) observed, as well as the impact of CXCR4 mutations on patient response.This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting fees or research funds from Abbvie, AstraZeneca, BeiGene, Casma, Cellectar, Janssen, Pharmcyclics, Roche, TG Therapeutics.
